Breakthroughs in #Alzheimers treatments are creating new opportunities & challenges for clinical trials. On 12/1 in DC, the USC Clinical Trial Recruitment Lab hosts a symposium exploring how to build faster, more inclusive trials to accelerate progress. https://t.co/BoJKZZe5cZ
📢 “These drugs can produce substantial weight loss that builds over time, but only for people who can afford to stay on them.”
Dr. Alison Sexton Ward of @USCSchaeffer discusses her research on real-world #GLP1 use at @ObesityWeek.
#OW2026@GoHealio
https://t.co/6rhcp7uC2V
Any short-term savings from Medicare’s most-favored nation demonstrations must be weighed against potential long-term harms to patients from reduced innovation, USC Schaeffer scholars argue in @JAMAHealthForum.
https://t.co/YtPmQmkAuk
As director of health analysis at the Congressional Budget Office until earlier this year, the author ultimately concluded that AI will tend to leave patients, enrollees, employers, and government facing mounting bills. | Forefront
@ChapinWhite | @USCSchaeffer
https://t.co/PZ9Eps62od
Even large employers who directly cover medical bills have limited insight into rising healthcare costs.
That's because they usually rely on third party admins, whose incentives often aren't aligned, USC Schaeffer's Erin Duffy writes in @FortuneMagazine.
https://t.co/ayox2JnIp1
Medicare drug plans can cover weight-loss medications when they’re approved for other uses. But very few do, finds news USC Schaeffer research.
https://t.co/frfghcNFJv
Virtually everyone agrees the No Surprises Act needs to be fixed.
In @RealClearHealth, USC Schaeffer’s Erin Duffy explains how to preserve the law’s hard-won consumer protections while ensuring arbitration is accessible, transparent and credible.
https://t.co/o7RjbUl45D
"We need to spend far more time thinking about the beneficiary experience."
Jonathan Blum of @USCSchaeffer on why fewer plan choices haven't made Medicare any less complex or costly for beneficiaries. #TheHillHealth
Watch the full conversation: https://t.co/MVJV9jwq7g
Ahead of Election Day, new polling through the Understanding America Study finds that most Americans want stronger regulation of AI and data centers. The sentiment spans party lines, geography, generations and AI use. https://t.co/NYIgwWWq3d
As the IRA rapidly reshapes Medicare Part D, patients and health plans are still adapting, USC Schaeffer’s Jonathan Blum told @thehill.
These changes will put pressure on Congress to consider how to sustainably finance the program, he said.
https://t.co/JyKN4BmOGX
In 1972, Great Britain raised the minimum school-leaving age by 1 year. Decades later, the reform resulted in fewer dementia diagnoses, according to new @PNASNews research from the Center for Economic and Social Research at USC Schaeffer. https://t.co/bBGFDcyZrh
🗓️What should Medicare beneficiaries know about the 2027 open enrollment period now underway?
USC Schaeffer's Jonathan Blum joins a discussion on affordability, access and choice hosted by @TheHillEvents this Wednesday.
✒️Register: https://t.co/5aSXL3Hx69
New guidelines for postpartum GLP-1 use come as prescribing among new mothers has surged in recent years, according to USC Schaeffer research cited by @WSJ.
A leading medical body’s guidelines on GLP-1 use during and after pregnancy have opened the door to using the drug while nursing. https://t.co/6tvmGQTczz
The ACA failed to bend the cost curve, USC Schaeffer's Dana Goldman writes in @statnews.
The good news: We now have the tools to get healthcare costs under control if we're willing to take a hard look at the value of treatments. https://t.co/2doWL3tN93
Medical billing is complex, and patients rarely have insight into how their bills are calculated.
A new USC Schaeffer issue brief examines the hidden infrastructure of medical billing and opportunities to improve the system.
https://t.co/GO7QYdMaJB
Nearly 40% of FDA advisory committee meetings over a recent 10-year period included a patient or consumer rep with active ties to an advocacy organization funded by drugmakers, according to new USC Schaeffer research in @Health_Affairs Scholar
https://t.co/WHutaDn7du
Unless their reviews better account for what patients actually pay and their ability to access treatments, prescription drug affordability boards "may alter reimbursement without resolving the problem they were created to address," writes USC Schaeffer's William Padula.
State boards were established to address legitimate concerns about prescription drug costs and patient affordability, but don’t use the right measures to assess what patients actually pay. | Forefront
William Padula | @USC
https://t.co/ZMdMNpBJxw
A CA ballot proposal to tax billionaires is being pitched as a way to offset federal healthcare cuts.
However, USC Schaeffer’s Glenn Melnick tells @KFFHealthNews that its ambiguous language could allow lawmakers to use the money for other purposes. https://t.co/e3411Pc5v2
New treatments that can slow #Alzheimers progression could provide significant value across society, with even greater benefits when treatment starts earlier, according to new USC Schaeffer research. https://t.co/aI3ycILcMK